Recombinant COVID-19 Vaccine (CHO Cell) (Zifivax) Approved for Emergency Use in Colombia

On January 22, 2022, Anhui Zhifei Longcom Biopharmaceutical Co., Ltd. (Zhifei Longcom), the wholly-owned subsidiary of Chongqing Zhifei Biological Products Co., Ltd. (“Zhifei” or “the Company”), received the document on the approval of Emergency Use Authorization (EUA) for the Recombinant COVID-19 Vaccine (CHO Cell) (Zifivax) in Colombia. EUA for Zifivax has been officially granted by INVIMA in its resolution 2022002030 of January 21, 2022.

Since the start of international collaboration on the Recombinant COVID-19 Vaccine in 2020, Zhifei have fully considered the international market demand and the industrialization capacity of our partners, and actively arranged regional localized production. At present, we have realized localized production and supply in Uzbekistan, and have started testing and validation of localized production in Indonesia. Colombia is a key regional country for our collaboration. The approval for emergency use of the Recombinant COVID-19 Vaccine will help the access and use of it in South American countries, and provide more and better vaccine choices for the international combating the COVID-19 pandemic.

About the Recombinant COVID-19 Vaccine (CHO Cell)

The Recombinant COVID-19 Vaccine (CHO Cell) is a recombinant protein subunit vaccine co-developed by IMCAS and Zhifei Longcom, the wholly-owned subsidiary of Zhifei. It is prepared by expressing purified pathogen antigen proteins in engineered cells by means of genetic engineering, and is with completely independent intellectual property rights. The vaccine was registered and marketed in Uzbekistan on March 1, 2021, becoming the first recombinant COVID-19 vaccine registered and marketed in the world. It was approved for emergency use in China, Indonesia and Colombia on March 10, 2021, October 7, 2021, and January 21, 2022, respectively.